Full Length Research Paper
References
|
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013). Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 369(9):799-808. |
|
|
Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H, Koren G (2014). Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet. Gynecol. 123(6):1256-61. |
|
|
Bapat P, Pinto LS, Lubetsky A, Aleksa K, Berger H, Koren G, Ito S (2016). Examining the transplacental passage of apixaban using the dually perfused human placenta. J. Thromb. Haemost. 14(7):1436-41. |
|
|
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010). Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363:2499-2510. |
|
|
Beasley BN, Unger EF, Temple R (2011). Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N. Engl. J. Med. 364(19):1788-1790. |
|
|
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W (2008). The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug. Metab. Dispos. 36(2):386-399. |
|
|
Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013). Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. 369(15):1406-1415. |
|
|
Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012). Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366:1287-1297. |
|
|
Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J (2016). Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J. Thromb. 41(1):206-32. |
|
|
Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG (2015). XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur. Heart J. 37(14):1145-53. |
|
|
Capodanno D, Capranzano P, Giacchi G, Calvi V, Tamburino C (2013). Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int. J. Cardiol. 167(4):1237-41. |
|
|
Chan KE, Edelman ER, Wenger JB,Thadhani RI, Maddux FW (2015). Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131(11):972-9. |
|
|
Clinical Trials.gov identifier: NCT02234843 (2014). EINSTEIN Junior Phase III: Oral Rivaroxaban in Children with Venous Thrombosis (EINSTEINJr). Avalaible at: |
|
|
ClinicalTrials.gov identifier: NCT02464969 (2015). Apixaban for the Acute Treatment of Venous Thromboembolism in Children. Available |
|
|
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361:1139-1151. |
|
|
DeWald TA, Becker RC (2014). The pharmacology of novel oral anticoagulants. J. Thromb. Thromb. 37(2):217-233. |
|
|
Di Nisio M, Middeldorp S, Büller HR (2005). Direct thrombin inhibitors. N. Engl. J. Med. 353(10):1028-40. |
|
|
Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kälebo P, Reilly P (2005). A new oral direct thrombin inhibitor, dabigatran etexilate compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. 3:103-11. |
|
|
European Medicines Agency (2016). Available at: View Accessed October 14, 2016. |
|
|
Ferns SJ, Naccarelli GV (2015). New oral anticoagulants: their role in stroke prevention in high-risk patients with atrial fibrillation. Med. Clin. North. Am. 99(4):759-80. |
|
|
Gallego P, Roldán V, Lip GY (2014). Novel oral anticoagulants in cardiovascular disease. J. Cardiovasc. Pharmacol. Ther. 19(1):34-44. |
|
|
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013). Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369(22):2093-2104. |
|
|
Gong IY, Kim RB (2013). Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can. J. Cardiol. 29(7 Suppl):S24-33. |
|
|
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011). Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11):981-992. |
|
|
Harder S, Graff J (2013). Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Euro. J. Clin. Pharmacol. 69(9):1617-1633. |
|
|
Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2016). Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17(10):1467-507. |
|
|
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130(23):2071-2104. |
|
|
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Euro. Heart J. 37(38):2893-2962. |
|
|
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M (2014). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Euro. Heart J. 35(43):3033-69. |
|
|
Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005). Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Euro. J. Clin. Pharmacol. 61:873-880. |
|
|
Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007). Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol. 47(2):218-26. |
|
|
Lip GY (2016). How to REVISIT the increasing "real world" evidence for stroke prevention in non-valvular atrial fibrillation? Curr. Med. Res. Opin. 32(12):2055-2057. |
|
|
Lip GY, Agnelli G (2014). Edoxaban: a focused review of its clinical pharmacology. Eur. Heart J. 35(28):1844-55. |
|
|
Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al (2016). Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb. Haemost.116(5):975-986. |
|
|
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S (2012). Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366(1):9-19. |
|
|
Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ (2012). Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am. J. Cardiol. 110(3):453-60. |
|
|
Mueck W, Stampfuss J, Kubitza D, Becka M (2014). Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin. Pharmacokinet. 53(1):1-16. |
|
|
Mungall D (2002). BIBR-1048 Boehringer Ingelheim. Curr. Opin. Investig. Drugs. 3(6):905-7. |
|
|
Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND (2016). Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest. 150(6):1302-1312. |
|
|
Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S (2010). Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J. Clin. Pharmacol. 50(7):743-53. |
|
|
Parasrampuria DA, Truitt KE (2016). Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin. Pharmacokinet. 55(6):641-55. |
|
|
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10):883-891. |
|
|
Potpara TS, Lip GY (2013). Novel oral anticoagulants in non-valvular atrial fibrillation. Best. Pract. Res. Clin. Haematol. 26(2):115-129. |
|
|
Raghavan N1, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D (2009). Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug. Metab. Dispos. 37(1):74-81. |
|
|
Raschi E, Bianchin M, Ageno W, De Ponti R, De Ponti F (2016). Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug. Saf. 39(12):1175-1187. |
|
|
Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M (2013). Edoxaban for the long-term treat-ment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trials. J. Thromb. Haemost. 11(7):1287-1294. |
|
|
Reiffel JA, Weitz JI, Reilly P, Kaminskas E, Sarich T, Sager P, Seltzer J (2016). NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. Am. Heart J. 177:74-86. |
|
|
Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB (2016). Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis. Circ. Cardiovasc. Qual. Outcomes 9(2):126-34. |
|
|
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 383(9921):955-62. |
|
|
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C (2014). Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764-772. |
|
|
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ (2009). Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361:2342-2352. |
|
|
Stangier J, Clemens A (2009). Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin. Appl. Thromb. Hemost. 15(Suppl 1):9S-16S. |
|
|
Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K (2008). Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J. Clin. Pharmacol. 48(12):1411-1419. |
|
|
Stangier J, Stähle H, Rathgen K, Fuhr R (2008). Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin. Pharmacokinet. 47(1):47-59. |
|
|
Stangier J, Rathgen K, Stähle H, Gansser D, Roth W (2007). The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombininhibitor, in healthy male subjects. Br. J. Clin. Pharmacol. 64(3):292-303. |
|
|
Stangier J, Rathgen K, Stähle H, Mazur D (2010). Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 49(4):259-68. |
|
|
Tummala R, Kavtaradze A, Gupta A, Ghosh RK (2016). Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data. Int. J. Cardiol. 214:292-8. |
|
|
U.S. Food and Drug Administration (2016). Available at: View Accessed October 14, 2016. |
|
|
Verheugt FW, Granger CB (2015). Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 386(9990):303-10. |
|
|
Villines TC, Peacock WF (2016). Safety of direct oral anticoagulants: insights from postmarketing studies. Am. J. Emerg. Med. 34(11S):9-13. |
|
|
Wong PC, Pinto DJ, Zhang D (2011). Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J. Thromb. Thromb. 31(4):478-92. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
